Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats
- 1 March 1992
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 118 (3) , 195-200
Abstract
The antineoplastic activity of the ruthenium complexestrans-imidazolium[tetrachlorobisimidazoleruthenate(III)], HIm(RuIm2Cl4),trans-indazolium-[tetrachlorobis(1H-indazole)ruthenate(III,N2)], HInd [RuInd2Cl4(N2)], andtrans-indazolium[tetrachlorobis(2H-indazole)ruthenate(III,N1)], HInd[RuInd2Cl4-(N1)] was assessed in acetoxymethylmethylnitrosamine-induced autochthonous colorectal carcinomas of Sprague-Dawley rats. The model is not sensitive to clinically established antineoplastic agents, including cisplatin. An exception is the combination therapy with 5-fluorouracil/leucovorin, which shows moderate activity against the tumour model. In contrast to this general trend, the new substances were all active against this tumour. HIm(RuIm2Cl4) was very effective at all dosages applied (7.5 mg/kg, 5.3 mg/kg, and 3.8 mg/kg), as indicated by percentage treated/control (T/C values of 23%, 34.5%, and 44%. Toxicity was considerable as shown by a body weight change of −30%, −19%, and −9%. Nevertheless, the medium dose seems to be the optimum in terms of mortality (0% vs 15% in the control group), whereas at the highest dose, mortality increased as a result of substance toxicity, and at the lowest dose mortality increased through tumor growth combined with substance toxicity. HInd[RuInd2Cl4(N2)] showed high efficacy at the highest dosage of 13 mg/kg, reaching a T/C value of 27% combined with 0% mortality versus 15% in the control group. In equimolar dosages (10 mg/kg, 7.1 mg/kg and 5.1 mg/kg), the compound is not as active as HIm-(RuIm2Cl4), as indicated by T/C values of 50.2%, 45.7%, and 38.6%. HInd[RuInd2Cl4(N1)] was slightly but not significantly better than HInd[RuInd2Cl4(N2)] at a dosage of 7.1 mg/kg and is advantageous over combination therapy with 5-fluorouracil and leucovorin (20/20 mg/kg) in terms of efficacy (T/C=37.6% versus 44.7%) and mortality (6% versus 33.3%).Keywords
This publication has 19 references indexed in Scilit:
- New Ruthenium Complexes for the Treatment of Cancer1989
- Postoperative Adjuvant Chemotherapy or BCG for Colon Cancer: Results From NSABP Protocol C-011JNCI: Journal of the National Cancer Institute, 1988
- Synthesis, molecular structure, and tumor-inhibiting properties of imidazolium trans-bis(imidazole)tetrachlororuthenate(III) and its methyl-substituted derivativesInorganic Chemistry, 1987
- Comparative antitumor activity of ruthenium derivatives with 5?-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD ratsCancer Chemotherapy and Pharmacology, 1987
- Maligne Tumoren des Kolons1986
- Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compoundsJournal of Cancer Research and Clinical Oncology, 1983
- Chemie der nitrosamine II. Synthese α-funktioneller dimethylnitrosamineTetrahedron Letters, 1975
- Evaluation of endoscopic examination of colon tumors in ratsDigestive Diseases and Sciences, 1975
- Errata: Use of Ranks in One-Criterion Variance AnalysisJournal of the American Statistical Association, 1953
- Use of Ranks in One-Criterion Variance AnalysisJournal of the American Statistical Association, 1952